UroGen Pharma Ltd. URGN

Latest FY: 2025 Healthcare Biotechnology
Market Price $44.87
Market Cap $2.19B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑21.4% YoY
$109.79M
3-Yr CAGR: 19.5%
Net Income ↓-21.0% YoY
-$153.49M
Net Margin: -139.8%
Free Cash Flow ↓-67.7% YoY
-$162.73M
FCF Yield: -7.44%
EPS (Diluted)
N/A
Basic: $-3.19
Return on Equity Efficiency
N/A
ROA: -76.6%
⚡ N/A due to negative equity (share buybacks or other)

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (URGN)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $17.5M $17.5M $-1.9M $4.2M $3.5M
FY 2017 $8.2M -53.5% $7.6M $-20.0M -930.4% 0.00% $-9.6M $-9.8M -381.7%
FY 2018 $1.1M -86.2% $-0.7M $-75.7M -278.3% 0.00% $-37.3M $-37.9M -285.0%
FY 2019 $0.0M -98.4% $0.0M $-105.1M -39.0% 0.00% $-71.0M $-71.3M -88.3%
FY 2020 $11.8M +65,450.0% $10.8M $-128.5M -22.2% 0.00% $-105.9M $-107.1M -50.1%
FY 2021 $48.0M +307.2% $42.9M $-110.8M +13.7% 0.00% $-84.9M $-85.6M +20.0%
FY 2022 $64.4M +34.0% $56.7M $-109.8M +0.9% 0.00% $-87.6M $-87.8M -2.5%
FY 2023 $82.7M +28.5% $73.4M $-102.2M +6.9% 0.00% $-76.4M $-76.6M +12.8%
FY 2024 $90.4M +9.3% $81.5M $-126.9M -24.1% 0.00% $-96.8M $-97.1M -26.8%
FY 2025 $109.8M +21.4% $97.3M $-153.5M -21.0% 0.00% $-162.4M $-162.7M -67.7%
$

Valuation

Market Price $44.87
Market Cap $2.19B
Enterprise Value $2.20B
P/E Ratio N/A
P/B Ratio N/A
FCF Yield -7.44%
Dividend Yield N/A
Shares Outstanding 48,721,700
%

Profitability & Margins

Gross Margin 88.66%
Operating Margin -113.73%
Net Margin -139.81%
Return on Equity (ROE) N/A (Negative Equity)
Return on Assets (ROA) -76.57%
Asset Turnover 0.55x
Revenue 3-Yr CAGR 19.49%
🛡️

Financial Health & Liquidity

Current Ratio 4.01
Cash Ratio 2.39
Debt / Equity -1.159
Debt / Assets 0.610
Cash & Equivalents $110.75M
Total Debt $122.21M
Book Value / Share $-2.16
💧

Cash Flow Efficiency

Operating Cash Flow -$162.44M
Capital Expenditures (CapEx) $289.00K
Free Cash Flow -$162.73M
OCF / Revenue -147.96%
FCF / Revenue -148.22%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) N/A
EPS (Basic) $-3.19
Dividends / Share N/A
Book Value / Share $-2.16
EPS YoY Growth N/A
🏛️

Balance Sheet (FY 2025)

Total Assets $200.46M
Total Liabilities $305.93M
Stockholders' Equity -$105.47M
Current Assets $186.02M
Current Liabilities $46.42M